Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online:319
  • Home
  • Print this page
  • Email this page
Year : 2016  |  Volume : 30  |  Issue : 3  |  Page : 166-170

Effect of botulinum Toxin-A in myofascial pain in temporomandibular disorders: A randomized, double-blinded, placebo-controlled study

1 Department of Dental and Maxillofacial Surgery, LHMC and SSKH, New Delhi, India
2 Department of Prosthodontics, ITS CDSR Dental College, Noida, Uttar Pradesh, India
3 Department of Neuroanaesthesia and Critical Care, Fortis Hospital, Noida, Uttar Pradesh, India

Correspondence Address:
Anurag Aggarwal
Department of Neuroanaesthesia and Critical Care, Fortis Hospital, Noida, Uttar Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0970-5333.198013

Rights and Permissions

Introduction: The temporomandibular disorders (TMDs) include a heterogeneous group of clinical conditions affecting the stomatognathic system and its related structures. It is characterized by pain specific to the maxillofacial region, and these disorders are the main cause of chronic facial pain and disability. Management of TMDs is challenging due to the unknown etiology and complex anatomy of the temporomandibular joint region. Aim and Objectives: To evaluate the effect of botulinum toxin type-A (BTX-A) on pain and day to day functional and social activities of myofascial pain with or without TMDs, and to compare the effectiveness of BTX-A with a placebo group with the aid of EMG and a Behavioural Questionnaire. Materials and Methods: The study was done on 24 patients randomly divided into two groups and each group contains 12 participants. The study group showed a statistically significant decrease in the muscle activity after 14 days, and the patients responded that there was a significant reduction in the pain and improvement in their day-to-day functional as well as social activities after BTX-A treatment with 8 months follow-up. Conclusion: BTX-A has been proven to have positive desired effects on patients with TMDs.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded292    
    Comments [Add]    
    Cited by others 1    

Recommend this journal